Charles River Laboratories International, Inc.

CRL • Medical - Diagnostics & Research

$288.50

▼ -4.85 (-1.65%)

Current price

EarningsLatest report: Jun 27, 2026

BALANCED PROFILENeutralConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Mixed profile. The company is not automatically unattractive, but valuation, growth, or balance-sheet evidence does not yet justify a stronger signal.

Market Cap

$13.99B

Growth

5.6%

Cash Flow

5/5

Trend

Stable

Evidence

Positive free cash flow · 10.46Consistent free cash flow · 5/5Weak profitability

Financial data as of: Jun 27, 2026, 12:00 AM UTCLast earnings update: Jun 27, 2026, 12:00 AM UTCLast profile update: Aug 7, 2026, 12:29 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$288.50

Change-1.65%

Shares Out48.49M

Market Cap$13.99B

Enterprise Value$16.82B

52W Range144.26 - 267.99

Beta1.40

P/E-58.66

P/S3.50

P/B4.93

P/FCF37.74

EV/Sales4.21

Price$288.50

Change-1.65%

Shares Out48.49M

Market Cap$13.99B

Enterprise Value$16.82B

52W Range144.26 - 267.99

Beta1.40

P/E-58.66

P/S3.50

P/B4.93

P/FCF37.74

EV/Sales4.21

EV/EBITDA22.92

EV/FCF45.40

Earnings Yield-1.70%

FCF Yield2.65%

Dividend Yield0.00%

Gross Margin30.52%

Oper. Margin12.65%

Profit Margin-3.59%

Debt/Eq0.97

Current Ratio1.29

Quick Ratio1.02

Revenue 5Y5.56%

FCF 5Y5.48%

Target$267.60

Target Upside-7.24%

Target Median$273.00

Target Range219.00 - 300.00

Volume1.31M

Avg Volume880.34K

EPS Surprise0.10

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

39/100

Financial Strength

Debt, cash, stability

65/100

Growth Potential

Revenue and expansion

44/100

Price Attractiveness

Cheap or expensive today

76/100

Why this score▼

Positive free cash flow · 10.46Consistent free cash flow · 5/5Weak profitability

Analyst view

Analyst sentiment and price target

CRL

Analyst sentiment

Based on 37 analyst votes · 2026-09-05

86/100

Bullish

Hold

Bearish

Price Target

2026-08-07

Low

$219.00

Mean

$255.78

Median

$250.00

High

$300.00

Company Overview

IPO: 6/23/2000

Industry: Medical - Diagnostics & Research

P/B i: 4.93

Debt / Equity i: 0.97

Operating Margin: 12.65%

Net Margin: -3.59%

ROE i: -

ROIC: -

Financial Health

Score13 / 20

Debt / Equity: 0.97

Current Ratio: 1.29

Quick Ratio: 1.02

Status: Good

Insider Transactions

Recent executive and insider activity

Parisotto Shannon M

Transaction: 08/05/2026

SELL

Change

-5,046

Price

$263.00

Filing

08/06/2026

Type

SELL

FOSTER JAMES C

Transaction: 06/29/2026

SELL

Change

-75,000

Price

$225.00

Filing

07/01/2026

Type

SELL

Parisotto Shannon M

Transaction: 06/05/2026

BUY

Change

+1,529

Price

Not reported

Filing

06/08/2026

Type

BUY

Insider	Type	Change	Price	Transaction	Filing
Parisotto Shannon M	SELL	-5,046	$263.00	08/05/2026	08/06/2026
FOSTER JAMES C	SELL	-75,000	$225.00	06/29/2026	07/01/2026
Parisotto Shannon M	BUY	+1,529	Not reported	06/05/2026	06/08/2026
Girshick Birgit	SELL	-3,386	Not reported	06/05/2026	06/08/2026
FOSTER JAMES C	SELL	-10,000	Not reported	06/05/2026	06/08/2026
Barg Steven	BUY	+422	$174.79	06/02/2026	06/03/2026
Parisotto Shannon M	SELL	-170	$180.71	05/31/2026	06/02/2026
Creamer Victoria L	SELL	-194	$180.71	05/31/2026	06/02/2026
Girshick Birgit	SELL	-378	$180.71	05/31/2026	06/02/2026
Knell Michael Gunnar	SELL	-48	$180.71	05/31/2026	06/02/2026
LaPlume Joseph W	SELL	-235	$180.71	05/31/2026	06/02/2026
Mintz Mark	SELL	-64	$180.71	05/31/2026	06/02/2026
Parisotto Shannon M	SELL	-551	$180.71	05/30/2026	06/02/2026
Creamer Victoria L	SELL	-616	$180.71	05/30/2026	06/02/2026
FOSTER JAMES C	SELL	-1,596	$180.71	05/30/2026	06/02/2026
Girshick Birgit	SELL	-1,204	$180.71	05/30/2026	06/02/2026
Knell Michael Gunnar	SELL	-152	$180.71	05/30/2026	06/02/2026
LaPlume Joseph W	SELL	-744	$180.71	05/30/2026	06/02/2026
Mintz Mark	SELL	-305	$180.71	05/30/2026	06/02/2026
Parisotto Shannon M	BUY	+4,361	$180.71	05/29/2026	06/02/2026

About the Company

Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Source - link

Peers

AVTR BAX BIO CAI DVA PEN QGEN RNA RVTY

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

Charles River (CRL) Up 10.5% Since Last Earnings Report: Can It Continue?

Charles River (CRL) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research

Is This the Right Time to Add CRL Stock to Your Portfolio?

Charles River's improving DSA demand and strategic investments support growth, but uneven recovery and NHP cost volatility remain key risks.

Zacks Investment Research

Contrasting Charles River Laboratories International (NYSE:CRL) and IB Acquisition (NASDAQ:IBAC)

Charles River Laboratories International (NYSE: CRL - Get Free Report) and IB Acquisition (NASDAQ: IBAC - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, risk and institutional ownership. Earnings and Valuation This table compares

Defense World

Wall Street Is Now Backing the Clarity Act. Here's the Most Likely Scenario for What Happens Next With Crypto.

According to prediction markets, final passage of the Clarity Act is not likely to happen until mid-2027 at the earliest. If the Clarity Act stalls out in Congress, the crypto industry will need to rely on favorable rule making from the likes of the SEC, CFTC, and OCC.

The Motley Fool

Great Lakes Advisors LLC Makes New $459,000 Investment in Charles River Laboratories International, Inc. $CRL

Great Lakes Advisors LLC purchased a new position in shares of Charles River Laboratories International, Inc. (NYSE: CRL) during the quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 2,026 shares of the medical research company's stock, valued at approximately $459,000. A

Defense World

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-05-07	1.96	2.06	0.1
2026-02-18	2.33	2.39	0.06
2025-11-05	2.32	2.43	0.11
2025-08-06	2.5	3.12	0.62
2025-05-07	2.06	2.34	0.28
2025-02-19	2.5	2.66	0.16
2024-11-06	2.42	2.59	0.17
2024-08-07	2.39	2.8	0.41
2024-05-09	2.06	2.27	0.21
2024-02-14	2.39	2.46	0.07
2023-11-08	2.35	2.72	0.37
2023-08-09	2.63	2.69	0.06